Autologous hematopoietic stem cell transplantation in elderly patients (>= 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study

Affiliation auteurs!!!! Error affiliation !!!!
TitreAutologous hematopoietic stem cell transplantation in elderly patients (>= 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study
Type de publicationJournal Article
Year of Publication2015
AuteursHermet E., Cabrespine A., Guieze R., Garnier A., Tempescul A., Lenain P., Bouabdallah R., Vilque J.P, Frayfer J., Bordessoule D., Sibon D., Janvier M., Caillot D., Biron P., Legros L., Choufi B., Drenou B., Gorin N.C, Bilger K., Tamburini J., Soussain C., Brechignac S., Bay J.O, Therap SFrancaise
JournalJOURNAL OF GERIATRIC ONCOLOGY
Volume6
Pagination346-352
Date PublishedSEP
Type of ArticleArticle
ISSN1879-4068
Mots-clésAutologous stem cell transplantation, elderly patients, High dose chemotherapy, non-Hodgkin lymphoma, Treatment related mortality
Résumé

{Introduction: Limited data is available on the feasibility of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) in elderly patients over 70 years of age with non-Hodgkin's lymphoma (NHL). Materials and Methods: In the setting of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) group, we retrospectively analyzed 81 consecutive patients with NHL over 70 years of age who received AHSCT. Results: The median age at AHSCT was 72.3 years [70-80]. Patients' were diagnosed with diffuse large B-cell lymphoma (n = 40), follicular lymphoma (n = 16), mantle cell lymphoma (n = 15), T-cell lymphoma (n = 5), and other (n = 5). Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) was 0 in 73% of patients. Main conditionings were BEAM (Carmustine-Etoposide-Cytarabine-Melphalan
DOI10.1016/j.jgo.2015.04.005